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EXPRESSION OF RNA NANOPARTICLES BASED ON BACTERIOPHAGE 
PHI29 PRNA IN ESCHERICHIA COLI AND BACILLUS SUBTILIS  
 
 
Currently, most of the RNAs used in lab research are prepared by in vitro 
transcription or chemical synthesis, which can be costly. In vivo expression in 
bacterial cells is another approach to RNA preparation that allows large scale 
production at a lower cost. However, there are some obstacles in bacterial 
expression, including RNA degradation in host cell, as well as RNA extraction and 
purification. tRNA and 5S RNA have been reported as scaffolds to circumvent the 
degradation problem. These scaffolds can not only make the RNA product survive 
in the cell but also increase the stability after extraction.  
The packaging RNA (pRNA) of bacteriophage phi29 is a small non-coding 
RNA with a compact structure. The three-way junction (3WJ) region from pRNA is 
a thermodynamically stable RNA motif good for constructing therapeutic RNA 
nanoparticles. The 3WJ can not only integrate multiple RNA modules, but also 
stabilize them.  
Here I report a series of approaches made to express recombinant RNAs based 
on pRNA or 3WJ in bacteria, including 1) Investigating the mechanism of RNA 
folding in vitro and in vivo using 3WJ. 3WJ-based RNAs were expressed in E. coli 
using pET system. The results show that the folding of RNA is affected by both 
overall and regional energy landscape. 2) Expression of an RNA nanoparticle 
harboring multiple functional modules, a model of therapeutic RNA, in E. coli 
using a combination of tRNA scaffold and pRNA-3WJ. The expression was 
successful and all of the RNA modules were functional. 3) Expression of 
pRNA-based recombinant RNAs in B. subtilis. This is a novel system of expressing 
recombinant RNAs in Gram-positive bacteria. 
 
KEYWORDS: pRNA, bacteriophage phi29, Bacillus subtilis, RNA expression, 
three-way junction 
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Chapter 1 Introduction 
1.1 In vivo expression of non-coding RNAs 
1.1.1 Background of recombinant RNA expression  
Novel functions and applications of RNAs have been discovered in recent 
decades, including siRNAs, aptamers, and ribozymes. While the interest in 
the potential usage of RNAs in biomedical and molecular studies is 
increasing, the fragile nature of RNAs is an obstacle in RNA studies. The 
recombinant protein expression system has contributed a lot to the studies of 
protein structure and function that it makes it possible to prepare proteins in 
large scale. [1] Similarly, finding a way to prepare RNA for high yield and with 
cost-efficiency is important in RNA studies. Currently most RNAs used in 
research are prepared by in vitro transcription or chemical synthesis, which 
are costly and difficult to operate on a large scale, or limit the length of 
product. [2] 
Compared to these in vitro approaches, in vivo expression is cheaper 
and much more practical in large scale. Nowadays recombinant plasmids 
are widely used in protein expression. Although these in vivo protein 
expression systems will make an mRNA before the protein is translated, 
most them are not feasible for making RNAs because the RNA products are 
often degraded quickly. The system needs to be redesigned to be available 
for RNA expression. The first three successful approaches of large scale 
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RNA preparation in E.coli were reported in 1988. [1, 3-5] Two of them were 
tRNAs and another was 5S ribosomal RNA. All these RNAs naturally exist in 
the host strain and have compacted structures, this may contribute to their 
stability in the cell. After the initial success, kinds of wild type and modified 
RNAs have been expressed in E.coli. In most recent approaches, different 
RNA structures were inserted into the anticoden loop, protecting them from 
being degraded by nucleases. [2] This offers a method of preparing desired 
RNA structures in vivo. Similar approaches were also made with 5s RNA. [6] 
1.1.2 Expression System 
Host Strain 
Escherichia coli (E. coli) is one of the most widely used bacterium in 
biological studies. The advantage of E. coli is that it grows fast and can be 
cultured large scale at low cost. Moreover, it produces RNAs with a very high 
efficiency. [2] 
Plasmid Vector for RNA Expression 
Just like the expression of recombinant proteins, a plasmid that is 
constructed for RNA expression generally contains elements including 
replication origin, promoter, multiple cloning site, and selection tags.  
One vector designed for RNA expression is constructed by inserting an 
lpp promoter and a downstream multiple cloning site into pBS plasmid. 
(Agilent Technologies). [59] It is derived from a suppressor tRNA encoding 
plasmid and it has been found thatrecombinant RNAs based on tRNA 
scaffolds can also be expressed. [2] Other research using 5S RNA scaffold 
has been based on the T7 expression system. [6] 
Promoters 
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T7 expression system and lpp promoter are widely used in the expression of 
recombinant RNAs. Each of them has advantages and drawbacks. The lpp 
promoter is one of the strongest known natural bacterial promoters and is 
available in a lot of strains. [60] The expression is constant and the efficiency 
is high. However, it cannot be regulated. The lac oparon-T7 system can be 
induced and also has a very high efficiency. This is a great advantage when 
the RNA product is toxic to the host, and it prevents the host from growing. 
But, its termination efficiency is poor; therefore it often makes undesirablely 
long products. Additionaly, it can only be used in some strains specifically 
designed for T7 expression, like BL21 (DE3). [2] 
1.1.3 RNA scaffolds 
Different kinds of structured RNAs has been tested to transcribe directly from 
a vector that works with tRNA, and the result has been heterogeneous. The 
product failed to accumulate to the desirable amount. Therefore, it has been 
found that the structure, rather than the vector, contributes to the stability of 
RNA products. 
The degradation of RNAs in bacteria is a complex process involving 
several kinds of RNase. Many of them will attack the terminal single strand, 
either the 5ʹ-end or the 3ʹ-end. A compacted double strand in the end is 
helpful to the survival of the RNA product. Unfortunately, in vivo transcription 
often makes a terminal single strand, especially at the 3ʹ-end. Unlike protein 
that has a stop codon to terminate translation at a specific site, the 
terminators of transcription are based on a stem-loop structure. The site of 
termination in transcription is often unspecific and the efficiency is rather low. 
[7] Thus, post transcriptional processing is important to make a compact 
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RNA structure that resists degradation. Flanking the desired RNA structure 
with scaffolds based on stable and abundant natural RNAs is an effective 
way to protect the product. The scaffold not only allows the product to be 
processed to give a compact end, but also mimics the product in the 
structure of a natural RNA, therefore greatly increases the stability of the 
product. [2] 
tRNA is one of the earliest available scaffolds found for recombinant 
RNA expression. The advantage of tRNA scaffold is the small size of the 
scaffold and high natural. There are up to 130,000 tRNA molecules per 
genome in the condition of exponential growth. For comparison, this is 
almost twice as the most abundant cytoplasmic protein, the elongation factor 
EF-Tu, which is approximately 75,000. [25] In previous applications the 
desired RNA is inserted into the anticodon loop. ΤψC and D stem-loops need 
to be kept to maintain the L-shape secondary structure as acceptor. 
Insertions up to approximately 300 nucleotides have been successfully 
expressed in tRNA scaffold. [2] 
Recent studies have also proven 5S RNA to be an effective scaffold for 
recombinant RNAs. There are around 12,500 ribosomes per cell and thus, 
the same number of 5S RNAs. Ribosomal RNAs are resistant to degradation 
and have a half life of several days. [12] The 5S RNA scaffold has some 
advantages that complement the tRNA, including different cloning strategy 
that allows overcoming the RNA misfolding problems in the tRNA scaffold 
designs. [6] In many case the scaffold will not affect the activity of the 
inserted elements. However, it is beneficial to remove the scaffold in many 
situations. The strategy of scaffold removal includes ribozymes, DNAzyme, 
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and RNase H. RNase H has been proven to work well in releasing the 
insertion from tRNA scaffold. [2] RNase H cleaves DNA-RNA hybrid double 
strands, therefore a complementary single strand DNA is needed for the 
cleavage. DNAzymes are catalytic DNA molecules, usually possessing 
specific cleavage activity like ribozymes.  
1.1.4 Elements That Have Been Successfully Expressed in vivo 
Currently there is a wide range of functional RNA elements that are available 
for in vivo expression. 
Malachite Green Aptamer (Fluorescence tag) 
Malachite Green (MG) is a triphenyl methane dye that has low fluorescence 
by itself, but the intensity of the fluorescence increases greatly when it is 
binding to an RNA aptamer. [48, 51] The MG aptamer is a compact double 
strand structure that has been expressed using either 5S RNA scaffold or 
tRNA scaffold. [2, 6] The MG fluorescence can be used in RNA tracking and 
quantification. 
Spinach Aptamer (Fluorescence tag) 
The fluorophore in Green fluorescent protein (GFP) is formed by 
intramolecular cyclization of three residues, Ser65-Tyr66-Gly67. The 
resulting fluorophore, 4-hydroxybenzlidene imidazolinone (HBI), is 
nonfluorescent by itself. It needs to be enclosed into a correctly folded GFP 
molecule to start the emission of fluorescence. [20] 
An RNA aptamer (spinach) has been discovered by SELEX that is able 
to bind to 3,5-dimethoxy-4-hydroxybenzylidene imidazolinone (DMHBI) and 
activate its fluorescence. This fluorogenic RNA aptamer processes a similar 
pattern of spectrum as EGFP, and the brightness of the fluorescence is 
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satisfying. This aptamer has been used as a fluorescent tag to observe the 
motion of 5S rRNA in living cells by fusing it to the 3' end of 5S rRNA. [19] 
Sephadex Aptamer (Affinity tag) 
The sephadex aptamer is acquired by in vitro selection. The specific binding 
provides an effective method of RNA purification using sephadex column.[8] 
High concentration of UREA is used in elution to denature the RNA and 
disturb the secondary structure of the aptamer, thus disable the binding. 
Streptavidin Aptamer (Affinity tag) 
Streptavidin is a protein acquired from Streptomyces avidinii that has very 
high affinity to biotin. Commercial streptavidin resin is now available. The 
streptavidin-binding RNA aptamer is developed by in vitro selection and 
offers an alternative way of RNA purification. [9] The capacity of streptavidin 
column is not as high as sephadex, but the RNA is eluted by biotin without 
denaturation. This is valuable when the folding of RNA product need to be 
preserved. 
Hammerhead ribozyme (Therapeutic application) 
A hammerhead ribozyme is found to be able to recognize and cleave the 
polyA signal in hepatitis B virus, thus disabling the virus. Applying this 
ribozyme to infested cells will inhibit the replication of hepatitis B virus. [10] In 
vivo expression makes large scale preparation of this kind of therapeutic 
RNAs more practicable. 
HIV-DIS (Self assembly) 
The HIV-1 type dimerization initiation signal (DIS) loop enables in vivo dimer 
formation. HIV-DIS is a stem-loop structure with complementary nucleotides 
in the loop. Dimer forms by forming basepairs through a loop-loop interaction. 
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This allows assemblage of two RNA molecules harboring different functional 
groups [11].  
 
1.2 The bacteriophage phi29 and its packaging motor 
1.2.1 Introduction of bacteriophage phi29 
Bacteriophage phi29 is a tailed dsDNA phage that infects Bacillus subtilis. 
Phi29 is one of the smallest and simplest known dsDNA phage. Like other 
viruses, the replication of phi29 contains two steps. First, the viral proteins, 
RNAs, and genome DNA are synthesized in the host. Then the components 
assemble to form an infectious unit. Prohead is the first particle assembled 
during the construction of virion, containing scaffolding protein (gp7), major 
capsid protein (gp8), head fibers (gp8.5). A dodecameric connector (gp10) is 
incorporated into the bottom of the prohead, which acts as a path for DNA 
packaging, as well as connecting the tail to the prohead. [21, 22] A 174-base 
RNA (pRNA) is attached to the connector. [24, 25] A virus-encoded ATPase 
(gp16) drives the 19.8 kbp phage genome into the prohead by viral ATPase 
(gp16). The process of packaging will trigger the release of gp7. [26] gp16 
and pRNA detach from the connector after the packaging is completed. After 
that, the lower collar, appendages, and tail knob are attached to the capsid to 
form a mature viral unit.  
1.2.2 The packaging motor of phi29 
During the process of phage assembly, the viral genome DNA is transported 
into the procapsid. This packaging process is entropically unfavorable and is 
driven by the hydrolysis of ATP. The packaging motor of phi29 is constructed 
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by three coaxial rings: the connector, the ATPase hexamer, and the pRNA 
hexamer. The connector is a dodecameric ring incorporated into the prohead. 
It is constructed by 12 copies of protein gp10 and serves as the pathway for 
the DNA. The hexametric DNase gp16 generates the energy needed for 
DNA translocation. The hexametric packaging RNA (pRNA) connects the 
ATPase to the connector. [27, 28] 
The packaging motor of bacterial phage phi29 has been studied for a 
long time. The one-way traffic of dsDNA through the channel of the 
connector has been verified by different methods, including voltage ramping, 
electrode polarity switching, and sedimentation force assessment. [29] 
However, the detailed mechanism of the one-way transportation is still 
unclear. Although a rotation model has been proposed, a later study 
revealed that none of the three layers of the motor rotate during the 
packaging process. [27, 28, 30] Recently, our laboratory has discovered a 
novel revolving mechanism. During packaging, dsDNA revolves along the 
channel wall of the connector. The affinity between the ATPase subunit and 
dsDNA is increased while the ATPase subunit is binding to an ATP molecule. 
The hydrolysis of ATP results in a conformational change and lower affinity 
for dsDNA, thus transfering the dsDNA to the next adjunct ATPase subunit. 
[27, 31] 
1.2.3 Phi29 packaging RNA  
The packaging RNA (pRNA) is essential for packaging the DNA into the 
prohead. [25] pRNA is an 174-nucelotide (nt) RNA encoded by the viral 
genome. The first 117 nt in pRNA is the functional domain; the rest is the 
3ʹ-domain, the terminator, that is not required for the packaging function. The 
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117 nt pRNA contains two domains, the gp16 binding domain (domain/motif 
1 in Fig.1) and the prohead binding domain (domain/motif 2-5 in Fig.1). The 
prohead binding domain is located at the central region of the pRNA. Two 
interlocking loops (right-hand loop, motif 3 and left hand loop, motif 5, Fig.1) 
containing complementary nucleotide sequence are located in this domain, 
allowing hexamer forming in the packaging motor. [16, 25, 32, 33] The 
sequence in the loops can also be engineered to form stable dimers, trimers, 
and other pRNA oligomers.  
The properties of pRNA make it a good vector for constructing RNA 
therapeutic RNA nanoparticles. First, the diameter of hexametric pRNA is 
around 30 nanometers (nm), which is suitable for endocytosis. Particles 
larger than 100 nm are difficult to be engulfed by the cells, while particles 
smaller than 20 nm can be cleaned out of the serum in a short time. [34] 
Secondly, the prohead binding domain and the gp16 binding domain fold 
independently. Therefore, the gp16 binding domain can be replaced by 
another sequence (e.g. siRNA) and the hexamer forming activity (that is 
induced by the left- and right-hand loop in prohead binding domain) will not 
be affected. [10] Moreover, while single strand RNAs can be vulnerable to 
RNase, small and compact RNAs constructed by double-strand motifs are 
often more stable. [2] 
Our laboratory has proven that pRNA can be used as a scaffold to escort 
siRNA or hepatitis B virus ribozyme (HBV ribozyme). While the HBV 
ribozyme is escorted by the pRNA its activity is even higher than the 
ribozyme itself. [10] It is possible that the stable double strand pRNA can 
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help the folding of ribozyme, making a larger portion of the ribozyme folded 
into the correct conformation.  
1.2.4 The three-way junction motif in phi29 pRNA 
The three-way junction (3WJ) motif is the central region of pRNA. It can be 
constructed by three synthesized single strand RNA oligos, denoted as a3WJ, 
b3WJ, and c3WJ. When the three RNA oligos are mixed in distilled water at 
room temperature in 1:1:1 ratio, they form the 3WJ motif automatically. 
Formed 3WJs remain stable in distilled water at room temperature for up to 
several weeks without dissociation. Moreover, the 3WJ does not dissociate 
in the presence of 8M UREA, which is common in denaturing buffers. The Tm 
of pRNA-3WJ is 58 C, which is significantly higher than most of similar RNA 
3WJ motifs. This evidence shows that the pRNA-3WJ is thermodynamically 
stable. [35] 
One of the problems in using therapeutic RNA nanoparticle, though, is 
that RNAs need to fold correctly to exhibit functions. Unlike proteins whose 
structure can be stabilized by disulfide bond, the folding of RNAs is 
maintained by hydrogen bonds and other weak interactions. Therefore, the 
folding of RNAs is relatively unstable because of the lack of covalent bonds 
and crosslinking. After systemic injection, the therapeutic RNA nanoparticle 
can be diluted into extremely low concentration. Further, although not always 
necessary, tens of millimoles of magnesium are required for the correct 
folding of many RNA motifs. However, under physiological conditions, the 
concentration of magnesium is usually lower than 1 mM. Therefore, 
misfolding or dissociation can occur to therapeutic RNA nanoparticles 
because of a low concentration of magnesium or a low concentration of RNA 
10 
 
itself. The pRNA-3WJ, however, is able to assemble automatically in distilled 
water without any magnesium added. In addition, it has been diluted to a 
concentration as low as 160 pM and there was no detectable dissociation. 
The stable nature of pRNA-3WJ makes it a potential scaffold to escort 
functional RNA modules, preventing them from dissociation or misfolding. 
[35, 36] 
 
 
Figure 1 Structure of phi29 pRNA. 
Structures of the components of phi29 DNA-packaging RNA (pRNA), 
showing its sequence in domains. The 3WJ domain sequence is highlighted 
in red. 
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Figure 2 Example of RNA expression using scaffold 
(A) E. coli tRNALys3. (B) E. coli tRNALys3 with anticodon loop replaced by 
malachite green (MG) aptamer. (C) Example of a plasmid engineered for 
RNA expression in bacteria [1, 2]. 
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Chapter 2 Study of RNA Folding Using the Malachite 
Green Aptamer 
2.1 Background 
Non-coding RNAs need to fold to appropriate tertiary structures in order to 
perform their intended functions. Until now, the folding of RNA has been 
studied for decades, and a lot of principles of RNA folding have been 
elucidated. However, most of them are based on in vitro studies. [37-39] The 
difference of RNA folding between in vitro and in vivo conditions is still 
unclear. The common methods of denaturing/reannealing (denaturing by 
high salt concentration or high temperature) RNAs in vitro are impractical in 
vivo. It is very difficult to change salt concentration in vivo. Heating would 
also kill the cells and possibly degrade the in vivo expressed RNAs. 
Several methods have been reported to be effective in elucidating RNA 
structure in vivo. Dimethyl sulfide (DMS) is sensitive to RNA structure and 
has been successful at probing RNA structure in a variety of organisms from 
bacteria to eukaryotes. [40-41] Lead-(II)-acetate has also been used to 
probe RNA structures in bacteria for its ability of inducing specific cleavages 
at the position of tight metal ion binding. [42] 
Here I report a different approach to studying RNA folding in vivo by the 
fluorogenic malachite green (MG) aptamer. The MG aptamer needs to fold 
into a double-strand conformation in order to bind to MG dye and fluoresce. 
The fluorescence will disappear when the aptamer is degraded or misfolded. 
Therefore, it can be used as a reporter of RNA folding both in vitro and in 
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vivo. I hypothesize that the presence of 3WJ will help the MG aptamer keep 
its correct conformation. 
2.2 MATERIALS AND METHODS 
2.2.1 Design of RNA constructs 
To investigate the mechanism of RNA both in vitro and in vivo, we designed 
an RNA nanostructure unit based on a thermodynamically stable pRNA-3WJ 
recently discovered by our laboratory. [35] The pRNA-3WJ acts as a scaffold 
to direct the folding and an MG-aptamer inserted into the 3WJ to serve as a 
folding reporter. The RNA constructs were named after the length and 
position of their interfering sequences: for example, “5ʹ+12” means that there 
were 12 nt added to the 5ʹ-end complementary to the MG-aptamer sequence, 
and “3 ʹ+15” means that there were 15 overhanging nt added to the 3ʹ-end 
complementary to the MG-aptamer sequence. Similarly, “3ʹNM+15” means 
that 15 nt non-complementary (NM = no match) to the MG-aptamer region 
were added to the 5ʹ-end of the pRNA 3WJ. 
During the transcription, the sequence at the 5ʹ-end was synthesized 
earlier than the sequence at the 3ʹ-end.  Single stranded nt of different 
lengths (6, 12, and 15) were added to the 5ʹ-end complementary to the MG 
aptamer sequence in order to interfere with the folding that was originally 
driven by the pRNA-3WJ (5ʹ+15, 5ʹ+12, and 5ʹ+6). (All RNAs constructed for 
in vitro assay were designed by Dan Shu.) 
Several controls were designed with overhanging nt of different lengths 
that did not match the MG aptamer sequence (5ʹNM+12, 5ʹNM+9, and 
5ʹNM+6). Another control contained 15 nt that matched the MG aptamer 
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inserted into the 3ʹ-end. Since the 3'-end would not come out until the entire 
MG aptamer had been synthesized during transcription, the 3'-end 
overhanging sequence was not expected to disturb the folding. 
Unlike protein translation, where expression starts after a ribosome 
receives a signal from the ATG start codon of mRNA and ceases at the 
corresponding stop codon(s), effective mechanisms of termination in RNA 
transcription are lacking. [43-45] Furthermore, the efficiency of the T7-TΦ 
RNA transcription terminator has shown to be about 66% by in vitro assays. 
[46] If the terminator failed to block the RNA polymerase, long RNA products 
would be transcribed; often, these RNA products have been subjected to 
rapid degradation. In addition, the terminator sequences undergo 
transcription and produce a stem-loop at the 3ʹ-end of RNA transcripts. This 
additional sequence would confront the experimental design. Therefore, we 
introduced a cis-acting ribozyme sequence placed at the 3'-end to avoid an 
unwanted sequence at the 3ʹ-end. [10, 47] 
2.2.2 In vitro synthesis and purification of RNAs  
3WJ RNAs harboring the MG aptamer and different insertions, used in MG 
aptamer fluorescence assay, were prepared by in vitro transcription using T7 
RNA polymerase. The DNA templates and primers were synthesized 
chemically by IDT (Iowa). DNA templates of in vivo transcription were 
amplified by PCR. RNAs were prepared by in vitro T7 transcription and then 
purified by 8 M urea 8% PAGE. The corresponding bands were excised 
under UV shadow and eluted from the gel for 4 h at 37°C in the elution buffer 
(0.5 M NH4OAc, 0.1 mM EDTA, 0.1% SDS, and 0.5 mM MgCl2), followed by 
ethanol precipitation overnight at -20°C (2.5x volume of 100% ethanol and 
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1/10 volume of 3M NaOAc). The precipitate was pelleted by centrifugation 
(16500 x g, 30 min), washed with 70% ethanol, and dried by speed vacuum. 
Finally, the RNA dried pellet was rehydrated in 0.05% DEPC treated water 
and stored at -20°C.  
2.2.3 Malachite Green (MG) aptamer fluorescence assay 
Gel-purified RNAs were mixed with MG (2 µM) in binding buffer containing 
100 mM KCl, 5 mM MgCl2, and 10 mM HEPES (pH 7.4) and incubated at 
room temperature for 30 min. The refolded RNAs (after heating) were treated 
by heating them to 95°C for 5 min before staining. The fluorescence was 
measured using a fluorospectrometer (Horiba Jobin Yvon; SPEX Fluolog-3), 
excited at 615 nm, and scanned from 625 to 800 nm for emission. [48, 49, 51] 
(The in vitro fluorescence assay was completed by Dan Shu.) 
2.2.4 Vector construction for in vivo expression 
A sequence of cis-ribozyme (Rz) was fused onto the 3ʹ-end of DNA 
templates of corresponding RNA for terminal processing. [47] Reference, 
5ʹ+6, 5ʹ+12, and 5ʹ+15 RNAs were inserted between BglII/NdeI sites of 
expression vector pET-3b. The BglII cleavage would remove the original T7 
promoter in the vector to prevent any undesired sequence in the 5ʹ-end of 
the RNA product. The insertion fragment contained the T7 promoter in its 
5ʹ-end. The cloning was completed in E. coli strain DH5α. The recombinant 
plasmids were verified by sequencing (GENEWIZ).  
2.2.5 RNA in vivo expression and purification 
E. coli strain BL21 (DE3) (Invitrogen) was transformed by the recombinant 
plasmids. The colony was inoculated by 5 ml LB medium containing 100 
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µg/ml ampicillin grown at 37°C and shaken at 250 rpm until A600nm reached 
0.5. IPTG solution of 50 µl (1 M) was added to 5 ml cell culture, cells were 
allowed to continue to grow for 1.5 h, and then were pelleted and 
resuspended in 250 µl of 10 mM magnesium acetate, 1 mM Tris-HCl, pH 7.4 
(buffer L; Ponchon et al. [50]). The total soluble RNAs were extracted using 
500 µl of water saturated phenol (pH 4.5) (Fisher). The aqueous phase was 
ethanol precipitated and then dissolved in 50 µl of 0.05% DEPC treated 
water. [1, 50] 
2.2.6 Gel electrophoresis of in vivo prepared RNAs 
In vivo expressed 5ʹ+0 (reference), 5ʹ+6, 5ʹ+12, and 5ʹ+15 RNAs were 
analyzed by PAGE gel by loading 5 µl of each sample. The denaturing gel 
was 8% PAGE gel containing 8 M of urea run in 1x TBE (89 mM Tris base, 
89 mM Boric acid, 2 mM EDTA) at 120 V at room temperature for 1 h. After 
electrophoresis, the gels were stained by 10 µM MG in binding buffer (100 
mM KCl, 5 mM MgCl2, and 10 mM HEPES, pH 7.4) for 15 min at room 
temperature. The MG fluorescence image was acquired by the Cy5 channel 
(635 nm excitation/670 nm observation) using a Typhoon scanner. [48, 51] 
The gels were then stained by Ethidium Bromide (EB) and scanned in an EB 
channel (532 nm excitation/580 nm observation). 
2.3 Results and Discussion 
2.3.1 In vitro comparison of 3WJ-pRNA folding after transcription 
and after denaturation/reannealing 
To reveal the folding differences of the pRNA-3WJ prior to and after 
denaturation/annealing, the spectrum of MG fluorescence was recorded 
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firstly when the transcription was completed. After that, the RNAs were 
heated to 95° C, and then cooled to room temperature. The fluorescence 
spectrum was measured again.  
RNA design 5'+0, 5'+6, 3’+15 and those with non-match insertions in 
5’-end exhibited similar fluorescence intensity before and after heating. 
However, for design 5’+12 and 5’+15, the intensity of fluorescence increased 
significantly after heating. Therefore, the folding of RNA was impacted by the 
length of 5’-interferece sequence. In the situation of the designs with long 
interference sequence in 5’-end, such as 5’+12 and 5’+15, the 5’-sequence 
would pair with the first several nucleotides in the MG aptamer, preventing 
the rest of the aptamer to fold. After heating and reannealing, the low free 
energy promoted the 3WJ to fold first, thus recovering the folding of MG 
aptamer. [35] The 3’-interference sequence had no effect on the folding, 
since the 3WJ-MG structure had already folded when the 3’-sequence was 
transcribed. The 5’-non-match sequences had no effect either, for they could 
not pair with the 3WJ-MG.  
2.3.2 In vivo assessment of the RNA folding after transcription 
To investigate the RNA folding in vivo, designed 5'+0, 5'+6, 5'+12 and 5'+15 
RNAs were expressed in E.coli BL21(DE3) strain. The sequences of in vivo 
designs were the same as those in vitro, but with an additional cis-ribozyme 
inserted to the 3ʹ-end to process the RNA product. Unlike protein expression 
that starts at the ATG codon and stops at the stop codon, effective 
mechanisms of termination are lacking in RNA transcription. The efficiency 
of T7-TΦ terminator has been found to be ~66% at in vitro assays. [46] Long 
RNA products would be transcribed if the terminator failed to block the RNA 
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polymerase. These RNAs are often degraded rapidly. Additionally, the 
terminator itself would be transcribed as a stem-loop in the 3ʹ-end of RNA 
product, which is undesired in this experiment. Therefore, we used a 
cis-ribozyme to remove the unwanted sequences in 3ʹ-end after transcription, 
thus reducing the additional sequence to only 7 nt. [10, 47] 
The RNA product of in vivo expression varies while the length of 
interference sequence changes. Designed 5'+0 and 5'+6 RNA products with 
MG binding activity were detected in MG-stained PAGE gels. However, 
when the interference sequences were longer in design, 5'+12 and 5'+15, 
there were hardly any products showing MG binding activity. Instead, there 
was a very small RNA fragment that could not be stained by MG. These 
results indicated that the folding of the designs with short insertions and 
those with longer insertions may have been different. In 5'+6 the 5ʹ 
interference sequence was not long enough to disturb the folding of 3WJ-MG, 
thus the 3WJ and MG aptamer folded normally and a complete RNA product 
was transcribed.  
In 5'+15 and 5'+12, the interference sequence would bind to the first 
strand of MG aptamer before the last part of the RNA, including the other 
strand of MG aptamer and C strand of the 3WJ, was transcribed. When the 
first strand of MG aptamer is transcribed, the RNA may fold as a long, 
GC-rich hairpin that resembles the structure of many terminators. This 
hairpin may stall the RNA polymerase and cause premature termination. On 
the other hand, if the transcription continues, the newly synthesized RNA will 
be left unpaired because their complementary sequences were already 
paired with the interference sequence. Single strand RNAs are much more 
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vulnerable to RNases than those with stable double strand. As a result, the 3ʹ 
region of the RNA can be degraded even though transcription continues. In 
both situations the product will be incomplete with only a part of the MG 
aptamer. Thus, the products of 5'+15 and 5'+12 were much smaller than 
expected and had no MG binding activity. 
The results of in vivo expression corresponded with the in vitro 
transcription before heating, but not after heating. In 5'+0 and 5'+12 the RNA 
folded normally and the product was complete with MG binding activity. In 
5'+12 and 5'+15, while the interference sequence was longer, the folding of 
3WJ and MG aptamer was disturbed. For in vitro transcription, this results in 
a misfolded MG aptamer whose activity can be recovered by denaturing and 
annealing. In the case of in vivo expression, the misfolding can cause 
degradation of unpaired sequences, resulting in an incomplete product. 
 
2.4 Conclusion 
The folding of RNA is affected by both overall and regional energy landscape. 
Sometimes motifs may form in 5ʹ region of RNA product during transcription, 
preventing the remaining part of RNA to fold correctly. RNA constructs 5’+12 
and 5ʹ+15 have a long interfering sequence in 5ʹ-end that was more likely to 
bind to the MG aptamer sequence, and thus prevent the folding of MG 
aptamer. After denaturation/annealing, these RNAs folded into the minimum 
energy structure. While expressed in living cells, the loose structure of 
misfolded RNAs can cause degradation. For in vitro transcription, the 
product can be denatured and refolded by changing temperature or contents 
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in the solution. For in vivo expression, however, the temperature is often 
stable, and denaturation/reannealing is not practical. Misfolded RNA 
products can be degraded rapidly. Predicted conformation of RNA during 
transcription needs to be taken into consideration for in vivo RNA 
expression. 
 
Acknowledgement: This RNA folding project was initially carried out by Dan 
Shu, who finished the in vitro study and concluded that long interference 
sequence in 5ʹ-end would disturb the folding of MG aptamer. I would like to 
thank Dr. Shu for allowing me to join this project and I am glad to contribute 
to this project with my skills in bacterial expression. Unlike the in vitro study, 
we were not able to get quantitative data for in vivo assessment because 
denaturation/reannealing is impractical in living cells. However, the in vivo 
results show some synergy with the in vitro data. The in vitro conclusion that 
long interference sequence in 5ʹ-end will disturb RNA folding was supported 
by the fact that these RNA designs were degraded in vivo. 
 
 
 
Figure 3 Folding assay of in vivo expressed pRNA-3WJ MG-apt.  
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(A) RNA construct design for in vivo folding studies. (B) 8% PAGE gel with 8 
M UREA, showing in vivo RNA products. For constructs 5ʹ+12 and 5’+15, 
whose folding could be disturbed by the interfering sequence in vitro, there 
was no correct product found in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 Expression of RNA nanoparticle harboring 
multiple functional elements in E. coli using tRNA 
scaffold 
3.1 Background 
So far, methods of massive production and purification in bacteria are only 
available for proteins. Most of the RNAs used in research are prepared by in 
vitro transcription or chemical synthesis, which can be costly in large scale or 
when producing long RNAs. Although in vivo expression of RNA has been 
considered as an alternate method, there are some obstacles. For example, 
RNA without a certain structure is vulnerable to RNase and can be degraded 
rapidly in living cell. The low efficiency of termination can often result in 
heterogeneous products. [52] Also, large scale purification of certain RNA 
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products can be difficult. Therefore, scaffolds based on native RNAs have 
been developed to protect RNA products from degradation, as well as 
allowing them to be processed by cellular enzymes. tRNA and 5S rRNA 
have been proven effective scaffolds for recombinant RNA expression. [2, 6] 
The stability and high copy number of tRNA make it a promising scaffold for 
large scale expression. In previous applications the exogenous RNA 
sequence is inserted into the anticodon loop. Insertions up to approximately 
300 nucleotides have been successfully expressed using the tRNA scaffold 
in E. coli. [2] 
Our lab has developed a tetravalent X-shaped RNA motif based on the 
pRNA-3WJ, which is able to carry up to four different RNA modules. For 
therapeutic RNA nanoparticles, multiple functional modules are often 
needed to be integrated into one molecule. [36] For example, one affinity tag 
is required to purify the RNA after production (e.g. streptavidin aptamer or 
sephadex aptamer), similar to his-tag or strep-tag in proteins. One 
fluorogenic tag is required to detect the transportation, folding and 
degradation of RNA after delivery (e.g. MG aptamer or spinach aptamer). 
Finally, one or more therapeutically active elements (e.g. siRNA, ribozymes, 
or riboswitches) are the most important part of therapeutic RNA nanoparticle. 
The 3WJ or X-shaped motif can not only integrate multiple modules into one 
RNA particle, but can also stabilize the folding of these modules. 
Here we report a method of combining both tRNA scaffold and 3WJ to 
make an RNA nanoparticle harboring multiple functional modules that can be 
expressed in E. coli in large scale. Although the pRNA can not be expressed 
in E.coli, the attempt of protecting the pRNA by tRNA scaffold is successful 
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[2]. Therefore, we hypothesize the 3WJ motif is also capable for E.coli 
expression with tRNA scaffold. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Design of RNA construct 
An X-shaped motif was constructed by combining one 3WJ and one 
reversed 3WJ. One of the four arms of the X-shaped motif was connected to 
the anti-codon loop of E. coli tRNALys3. The MG aptamer, streptavidin 
aptamer, and HBV ribozyme were connected to the other three arms. (Fig. 
4B) This RNA will be described hereafter as tRNA-MG-HBV-STV. 
3.2.2 Construction of expression vector 
The tRNA expression vector was constructed using the method developed 
by L. Ponchon and F. Dardel. [2] The lpp promoter, rrnC terminator, and 
several restriction sites were inserted between SacI and XhoI sites of 
pBluescript II SK (+/-) (pBS). (Fig. 4A) (The construction was done by 
Keyclone Technologies). This plasmid will be described hereafter as 
pBS-lpp. 
Template DNA sequence of tRNA-MG-HBV-STV was acquired by 
overlap PCR and cloned between EcoRI/HindIII sites in plasmid pBS-lpp. 
The cloning was completed in E. coli strain DH5α. The recombinant plasmids 
were verified by sequencing (GENEWIZ). 
3.2.3 RNA expression and extraction 
E. coli strain DH5α containing pBS-lpp with tRNA-MG-HBV-STV sequence 
inserted was inoculated into 1 liter of LB medium containing 100 µg/ml 
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ampicillin and was grown at 37°C shaker at 250 rpm for 16 hr. Cells were 
pelleted and resuspended in 10 ml of 10 mM magnesium acetate, 1 mM 
Tris-HCl, pH 7.4 (buffer L; Ponchon et al. [50]). The total soluble RNAs were 
extracted using 12 ml of water saturated phenol (pH 4.5) (Fisher). The 
aqueous phase was ethanol precipitated then dissolved in 1.5 ml of 0.05% 
DEPC treated water. 
3.2.4 Purification of tRNA-MG-HBV-STV from agarose gel 
The extracted RNA was loaded into 1% agarose gel and separated by 
electrophoresis at 121 V for 30 min in 1x TAE buffer (40 mM Tris-acetate, 1 
mM EDTA, pH 8.0). The band of tRNA-MG-HBV-STV was cut down and 
sealed in a dialysis bag (3000 MWCO) with 1 ml of TAE. The bag was put 
back to the electrophoresis chamber and the electrophoresis was continued 
at 150 V for 15 min. In the last 30 s of the electrophoresis, the electrodes 
were inverted to release the RNAs attached to the dialysis bag. After 
electrophoresis, the solution inside the bag was collected. The purified RNAs 
were concentrated by ethanol precipitation. 
3.2.5 Streptavidin binding test 
The tRNA-MG-HBV-STV sample was loaded to streptavidin resin in 1x PBS 
buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 ) [13] 
containing 10 mM of additional MgCl2. The resin was washed by the same 
buffer. Then, the RNA was eluted by 5 mM of biotin. Samples were collected 
during washing and elution and verified in 8% 8 M UREA PAGE in 1x TBE by 
MG and EB staining, as described in 2.2.6. [9] 
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3.2.6 HBV ribozyme cleavage assay 
The DNA substrate of HBV ribozyme was tagged by Cy3. The cleavage 
reaction was performed at 37°C in 20 mM Tris (pH 7.5) and 20 mM MgCl2 for 
60 min. An in vitro transcribed, pRNA escorted HBV ribozyme was used as 
positive control of cleavage. The result of cleavage was confirmed in 8% 8 M 
UREA PAGE in 1x TBE. [10] 
 
3.3 Result and Discussion 
3.3.1 Verifying the function of MG aptamer, streptavidin aptamer, 
and HBV ribozyme  
In vivo product of pRNA-MG-HVB-STV was able to bind streptavidin resin. 
Bound RNA can be eluted competitively by 5 mM biotin. (Fig. 5B) The 
cleavage of HBV ribozyme had been confirmed (Fig. 5A), however, the 
efficiency of cleavage was lower than the positive control (pRNA escorted 
HBV ribozyme, lane 2). This could be caused by the structure of RNA rather 
than in vivo expression, since both in vivo expressed and in vitro transcribed 
pRNA-MG-HVB-STV presented similar cleavage efficiency. It was possible 
that different modules in the RNA molecule could interfere with each other, 
since the result of HBV ribozyme was positive. The MG fluorescence was 
detected even in the denaturing gel (Fig. 5A). Connecting to the 3WJ would 
stabilize the MG aptamer, protecting its conformation under the presence of 
8 M UREA. 
The design of pRNA-MG-HVB-STV is an example of hypothesized 
therapeutic RNA nanoparticle. After production, it can be purified using 
streptavidin column. The HBV ribozyme is a therapeutic module which can 
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destroy viral genome. After delivery, the presence of the RNA can be 
observed by MG fluorescence. Our laboratory has created a lot of RNA 
nanoparticles based on pRNA 3WJ, harboring multiple functional modules. 
[36, 53] The result of this experiment reveals the possibility of massive 
production of these RNA nanoparticles in bacteria. 
3.3.2 The yield of RNA production 
Roughly 5 mg of purified pRNA-MG-HVB-STV was acquired from 1 L of E. 
coli culture. This is less than the reported yield (10-50 mg) of other 
recombinant RNAs based on tRNA scaffold. [2] One possible reason of the 
reduction in yield is the HBV ribozyme, which has a single strand region in its 
hammerhead. Single strand regions are vulnerable to RNases even when 
they are in the middle of the RNA. Another possible reason is that our RNA 
was purified from agarose gel, in which more samples could be lost when 
comparing with the chromatography used by L. Ponchon and F. Dardel. [1,2] 
 
3.4 Conclusion 
The pRNA 3WJ is a potential scaffold for therapeutic RNA nanoparticles, it is 
able to harbor multiple elements and stabilize them. Until now, these 
pRNA-based nanoparticles were made mainly by in vitro transcription. In this 
project we incorporated the 3WJ and the tRNA scaffold to express 
3WJ-based RNA nanoparticles in E. coli. The in vivo product of 
pRNA-MG-HBV-STV has been acquired successfully, with all three modules 
proving functional, thus demonstrating the viability of massive production of 
3WJ-based RNA nanoparticle in vivo.  The current method is not perfect, 
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yet. Further study is required to improve the yield of expression, as well as 
the compatibility of different modules.  
 
 
Figure 4 Design of tRNA-MG-HBV-STV  
(A) The expression region of tRNA expression vector (refered as pBS-lpp). 
The lpp promoter, rrnC terminator and several restriction sites are inserted 
between SacI and XhoI sites of pBluescript II SK (+/-) (pBS). (Keyclone 
Technologies). (B) Construct of tRNA-MG-HBV-STV. The MG aptamer, 
streptavidin aptamer, and HBV ribozyme were incorporated into the 
anti-codon loop of E. coli tRNALys3 using an X-shaped motif. 
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 Figure 5 Activity of the aptamers and ribozyme in tRNA-MG-HBV-STV 
(A) HBV ribozyme cleavage of DNA substrate labeled by Cy3. Cy3 channel 
shows the DNA substrate, MG channel shows tRNA-MG-HBV-STV, EB 
channel shows all DNAs and RNAs. Lane 1: substrate only. Lane 2: 
substrate and HBV ribozyme escorted by pRNA as positive control of 
cleavage, cleaved substrate appears as a lower band in Cy3 channel. Lane 
3: substrate and cell-expressed tRNA-MG-HBV-STV, cleavage detected in 
Cy3 channel, the MG fluorescence of tRNA-MG-HBV-STV detected at Cy5 
channel. Lane 4-5: substrate and in vitro transcribed tRNA-MG-HBV-STV, 
cleavage detected in Cy3 channel, the MG fluorescence of 
tRNA-MG-HBV-STV detected at Cy5 channel. Lane 6: tRNA-MG-HBV-STV, 
purified from cell. Lane 7: tRNA-MG-HBV-STV, made by in vitro transcription. 
(B) MG fluorescence and streptavidin binding. The tRNA-MG-HBV-STV 
sample was extracted from E. coli and purified from agarose gel. 1: 
tRNA-MG-HBV-STV before loading to streptavidin column, 2: unbound RNA, 
3: wash 4-5: elution. 
Acknowledgement: Thanks to Dan Shu for the gel images. 
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Figure 6 AFM image of tRNA-MG-HBV-STV 
tRNA-MG-HBV-STV expressed in E. coli and purified from gel. An overall “X” 
shape is apparent. (scale: nm) 
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Chapter 4 RNA Expression in Bacillus subtilis Using 
Phi29 pRNA as Scaffold 
4.1 Background 
An efficient method of recombinant RNA expression has been developed in 
E. coli using tRNA and 5S rRNA as a scaffold. [2, 6] However, until now, not 
a lot of attempts have been made to express recombinant RNAs in 
gram-positive bacteria.  
Currently most of the RNA extraction kits and reagents are primarily 
designed for animal cells. When applied to bacteria, cell lysis can become a 
problem. Gram-negative bacteria like E. coli are often lysed under harsh 
conditions (e.g. SDS/NaOH, phenol). [50, 54] These reagents make the kits 
unavailable. Additionally, phenol or detergents need to be removed after 
RNA extraction, or they may denature the RNA product. Most RNA 
extraction kits suggest crushing the bacteria cells mechanically using a 
homogenizer or a French Press. However, RNA degradation should be 
taken into consideration since cellular nuclease will not be deactivated in this 
way. On the other hand, the cell wall of gram-positive bacteria can be 
removed by lysozyme, leaving the protoplasts. [55, 56] Protoplasts can be 
simply lysed using the same method as animal cells, and the reagents are 
often offered in the kits. 
Our lab has developed many RNA nanoparticles based on phi29 pRNA 
or 3WJ. [10, 36, 53] Most of them are prepared by in vitro transcription. In 
one of our previous studies, pRNA was designed as a scaffold to escort the 
HBV ribozyme. Animal cells were transfected by DNA sequence of pRNA 
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with HBV ribozyme insertion. The cleavage activity of HBV ribozyme was 
confirmed in the cells. [10] However, no efforts had been made to observe or 
extract the RNA product, and the amount of RNA product was not 
determined. To study the function of pRNA, wild-type pRNA has been 
expressed in B. subtilis, as well as pRNAs with several modified bases. [24] 
But, pRNA’s capacity of being a scaffold to escort functional elements in 
large scale expression has not been verified. 
The strategy of expressing recombinant RNAs in E. coli uses a natural 
RNA (tRNA or 5S rRNA) as scaffold to deceive the cell, rendering the 
exogenous RNAs as harmless natural products. The structure of the scaffold 
plays an important role of the stability of RNA product. [2, 6] Unfortunately, 
phi29 pRNA is recognized as alien by E. coli. Although we have been able to 
express the pRNA-3WJ in E. coli using T7 expression system, applying the 
same method to full-length pRNA results in degradation of RNA product. On 
the other hand, B. subtilis is the natural host of phi29, and pRNA is rather 
stable in B. subtilis. The full gene of wild-type pRNA, including the promoter 
and terminator, has been cloned into a plasmid for B. subtilis expression. 
The amount of pRNA product has been satisfying. [24] Here we report the 
result of the RNA expression in B. subtilis, using phi29 pRNA as scaffold to 
escort exogenous RNA modules. We hypothesize that some regions of the 
pRNA can be replaced by functional RNA elements while the RNA is still 
stable in B.subtilis. 
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4.2 MATERIALS AND METHODS 
4.2.1 Design of RNA constructs 
We used fluorogenic RNA aptamers because they are easily detected. In our 
first attempt, MG aptamer was inserted into the left-hand loop of pRNA 
(pRNA-MG). (Fig.7A) In another design, the head-loop of pRNA was 
replaced by spinach aptamer (pRNA-spi). (Fig.7B) To test pRNA’s capacity 
to harboring more than one functional module, both MG aptamer and 
spinach aptamer were integrated into the left-hand loop of pRNA using a 
reversed 3WJ (pRNA-MG-spi). (Fig.7C) Template DNA sequences of 
pRNA-MG, pRNA-spi, and pRNA-MG-spi were acquired by overlap PCR. 
4.2.2 Construction of expression vector 
Shuttle vector pHT315 has been created by O. Arantes and D. Lereclus that 
can replicate in either E. coli or Bacillus. pHT315 was constructed by 
inserting Bacillus replication origin, erythromycin resistant gene, and multiple 
cloning site into E. coli vector pUC19. [58] 
In our experiment, template DNA sequence of pRNA-MG/ pRNA-spi/ 
pRNA-MG-spi was inserted between EcoRI/XbaI sites in pHT315. The 
cloning was completed in E. coli strain DH5α. The recombinant plasmids 
were verified by sequencing (GENEWIZ). 
4.2.3 Bacillus subtilis transformation 
B. subtilis strain 12A was transformed following the method by S. Chang and 
S. N. Cohen, 1979. [23] SMM buffer (0.5 M sucrose, 0.02 M Maleate and 
0.02 M MgCl2, pH 6.5. Wyrick and Rogers, 1973 [57]) was used to maintain 
the osmotic pressure and prevent the protoplast from lysis. SMMP medium 
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was prepared by mixing equal volumes of 4 X Penassay broth (Difco 
Antibiotic Metium 3) and 2 X SMM. B. subtilis 12A was grown in 37°C shaker 
until mid-log phase. Cells were harvested and resuspended in 1/10 volume 
of SMMP containing 2 mg/ml lysozyme. The resuspended cells were 
incubated at 37°C with gentle shaking for 2 hr to form protoplasts. After that, 
the protoplasts were pelleted and washed by SMMP to remove lysozyme, 
then resuspended in the same volume of SMMP. 
For each transformation, 500 μl of protoplast was mixed with 1.5 ml of 30% 
PEG 8000 in 1X SMM (w/v), as well as 500 ng of plasmid. Two minutes later, 
5 ml of SMMP was added to the mixture. The protoplasts were pelleted again 
and resuspended in 1 ml of SMMP, then incubated at 30°C for 1.5 hr with 
gentle shaking at 100 rpm. 200 μl of the protoplasts were plated on DM3 
regeneration medium (for one liter, 200 ml 4% agar, 500 ml 1 M sodium 
succinate (pH 7.3), 100 ml 5% Casamino acids, 50 ml 10% yeast extract, 
100 ml 3.5% K2HPO4 and 1.5% KH2PO4, 25 ml 20% glucose, 20 ml 1 M 
MgCl2, and 5 ml 2% bovine serum albumin (sterilized by filtering, added to 
the mixture when the temperature is about 55°C after autoclave)). The 
recovered colonies were transferred to LB plate containing 25 μg/ml 
erythromycin for selection. [23] 
4.2.4 Fluorescence assay of living B.subtilis cells 
Overnight culture of B. subtilis expressing pRNA-MG/ pRNA-spi/ 
pRNA-MG-spi was pelleted and resuspended in 2 volumes of binding buffer 
containing 100 mM KCl, 5 mM MgCl2, and 10 mM HEPES (pH 7.4). To 
detect MG fluorescence, 2 μM MG dye was added to the solution. To detect 
spinach fluorescence, 2 μM DFHBI was added to the solution. [19] The cell 
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suspension was incubated at room temperature for 30 min. The fluorescence 
was measured using a fluorospectrometer (Horiba Jobin Yvon; SPEX 
Fluolog-3). The MG fluorescence was excited at 570 nm, and scanned from 
600 to 800 nm to detect emission. [48, 49] The spinach fluorescence was 
excited at 450 nm, and scanned from 570 to 700 nm to detect emission. [19] 
To acquire the microscope image of living B. subtilis cells, overnight culture 
of expressing pRNA-MG-spi was pelleted and resuspended in 1/2 volume of 
binding buffer containing 5 μM MG dye (for MG fluorescence) or DFHBI (for 
spinach fluorescence). The cell suspension was incubated at room 
temperature for 30 min. 3 μl of cells was added to a slide and examined 
under Olympus FLUOVIEW FV1000 confocal laser scanning microscope 
using a 60X oil lens. MG fluorescence was acquired by Cy5 channel, and 
spinach fluorescence was acquired by Cy2 channel. 
4.2.5 RNA extraction from B.subtilis 
B. subtilis expressing pRNA-MG/ pRNA-spi/ pRNA-MG-spi was inoculated 
into 10 ml of LB broth containing 25 μg/ml erythromycin and grown in 37°C 
shaker at 250 rpm for 14 h. Cells were pelleted at 4,000 rpm for 10 min at 
room temperature, and then resuspended in 1 ml of 1X SMM containing 5 
mg of lysozyme and 2 u RNase-free DNase I. [23, 57] Protoplasts were 
formed by incubating at 37°C for 30 min. After that, RNA was extracted from 
the protoplasts using RNeasy Mini Kit (QIAGEN), following the instructions 
from the official manual. 
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4.2.6 Fluorescence assay of extracted RNA 
The extracted RNAs were analyzed in 8% PAGE gel in 1x TBE (89 mM Tris 
base, 89 mM Boric acid, 2 mM EDTA). After electrophoresis, the gels were 
stained by 5 µM DFHBI in binding buffer (100 mM KCl, 5 mM MgCl2, and 10 
mM HEPES, pH 7.4) and scanned using the Cy2 channel (473 nm 
excitation/520 nm observation) of Typhoon scanner to acquire the spinach 
fluorescence signal. After that, the gel was stained by 5 µM MG dye in 
binding buffer and scanned using the Cy5 channel (635 nm excitation/670 
nm observation) to acquire the MG fluorescence signal. Finally, the gel was 
stained by Ethidium Bromide (E. B.) and then scanned in the E. B. channel 
(532 nm excitation/580 nm observation) to display the total RNA. 
The MG and spinach fluorescence spectrums of extracted RNAs were 
also acquired using the same method described in 4.2.4. 
 
4.3 Result and Discussion 
4.3.1 Verifying the RNA products 
The fluorescence activity of both MG aptamer and spinach aptamer has 
been confirmed by spectrum. For cells expressing pRNA-MG, the emission 
peak was discovered at 650 nm. [48, 51] For cells expressing pRNA-spi, the 
emission peak was discovered at 500 nm. [20] For cells expressing 
pRNA-MG-spi, both peaks were detected, but not as high as the constructs 
with only one aptamer inserted. Fluorescence assay of extracted RNAs had 
a similar result. The peaks were more obvious since there was not a cell 
background. 
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For cells expressing pRNA-MG-spi, both MG and spinach fluorescence 
have been observed under confocal microscope. (Fig. 10) The intensity of 
fluorescence differs from cell to cell. This is possibly caused by different 
levels of expression. It is important to use freshly transformed cells for 
expression, since constant expression of RNAs is a burden on growth. Cells 
that produce more RNA product may grow slower, thus finally eliminated by 
selection, leaving only those have a low level of expression. [1] 
The fluorescence was also visible in PAGE gel of extracted RNAs. (Fig. 
9) The size difference was caused by different length of insertions.  
4.3.2 The method of RNA extraction and purification 
Total soluble RNAs can also be extracted from the protoplasts using phenol 
extraction, as described in 3.2.3. [1] However, the purity of RNA product is 
not as good as using the RNeasy kit. The MG fluorescence can be detected 
immediately after phenol extraction and ethanol precipitation. The spinach 
fluorescence, however, is missing. The RNA needs to be cleaned by passing 
through a NucAway Spin column (Invitrogen) to recover its spinach 
fluorescence. The structure of spinach aptamer is more flexible than the 
double-strand MG aptamer. Therefore the spinach aptamer is possibly 
denatured by the phenol left after ethanol precipitation. While using the 
RNeasy kits, the RNA product is ready to use immediately after purification. 
For E. coli, it is difficult to remove the cell wall completely. Additional steps of 
cell lysis (e.g. homogenizer) are required before the kit can be used. This is 
why phenol extraction is preferred in E. coli, since the cell lysis and RNA 
extraction can be completed in one step. For B. subtilis, the cell wall can be 
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easily removed by lysozyme digestion. Thus, the kit is preferred for a better 
quality product. 
4.3.3 Current limitations of pRNA scaffold 
Although we were able to acquire the expected product of pRNA-MG-spi, its 
amount was significantly less than pRNA-MG or pRNA-spi. It seems the long 
insertion had an impact on the stability of RNA. To protect the RNA from 
being degraded it is important to maintain a compact structure. While using 
tRNA as scaffold, only the anti-codon loop can be replaced by the insertion. 
[2] There are three loops in phi29 pRNA that can be replaced by insertions 
without changing the 3WJ structure. We found each of the three loops can 
be replaced by the MG aptamer, and that the amount of product is satisfying. 
However, when all three loops were replaced by insertions (one by MG 
aptamer, one by streptavidin aptamer, one by HBV ribozyme), there was no 
detectable product. In addition we were not able to alter the sequence at 
either the 5ʹ or 3ʹ end of pRNA. 
Currently the amount of RNA product with large insertions is not as good 
as desired. One possible solution to this problem is the modification of the 
host strain. In our experiment expressing 3WJ in E. coli (Chapter 2) we tried 
both regular BL21 (DE3) and BL21 Star (DE3) (Invitrogen) whose RNase E 
is disabled by mutation. The results withBL21 Star (DE3) were better, with 
more RNA product. Therefore, selecting a suitable host strain can be 
important for RNA in vivo expression. Bacterial expression of proteins is 
common; and there are a lot of commercially viable strains that are designed 
for protein expression. On the other hand, very few strains are engineered 
specifically for RNA expression, if any. Therefore, we may need to create a 
38 
 
modified (e.g. deletion of RNases) strain for the best result of RNA 
expression. 
 
4.4 Conclusion 
Full-length phi29 pRNA is unstable in E. coli. However, it can be produced in 
a satisfying amount in B. subtilis, which is the natural host of phi29. 
Therefore, pRNA is a potential scaffold for large scale RNA expression in B. 
subtilis. The attempt to insert one aptamer into pRNA is successful. Currently 
we are able to replace one of the three loops of pRNA with an aptamer. 
However, while both MG and spinach aptamers are integrated into one loop, 
the amount of RNA product is significantly reduced. It is possible that both 
the pRNA scaffold and the host strain need to be modified to express large 
RNA insertions. Although further improvements are needed, the pRNA 
scaffold in B. subtilis is a potential system for large scale expression of 
recombinant RNA. The Gram-positive nature of B. subtilis will bring some 
advantages over E. coli in cell lysis and RNA extraction. For example, the 
cell wall can be easily removed by lysozyme, allowing the commercially 
viable RNA purification kits to be used easily. 
 
Acknowledgement: Thanks to Dan Shu for designing the pRNA-MG, our first 
recombinant RNA that is available for B. subtilis expressioin. My design of 
pRNA-MG-spi was also inspired by previous RNA designs made by Shu for 
in vitro study. 
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4.5 Work in progress and failed attempts 
Besides the designs described in this chapter, we also tested a series of 
different RNA constructions for bacterial expression. Some of them work was 
completed as desired, but the rest of them failed to make expected products. 
The result shows that, for an RNA molecule, its viability of in vivo expression 
heavily depends on the structure. 
Besides the pRNA-MG design that integrated the MG aptamer into the 
left-hand loop, we also tried replacing the right-hand loop, or the head loop, 
by MG aptamer and the result was similar. However, we encountered 
problems replacing more than one of the loops in pRNA. One of the designs 
had the head loop replaced by spinach aptamer and the left-hand loop 
replaced by MG aptamer. Both MG and spinach fluorescence are detected in 
living cell. However, the extracted RNA showed several unexpected bands in 
UREA PAGE gel, suggesting degradation of product. This is why we 
integrated both MG and spinach aptamers into one loop in design 
pRNA-MG-spi. The attempt to replace all three loops (one by MG aptamer, 
one by streptavidin aptamer, one by HBV ribozyme) resulted in no detectable 
product. It was important to maintain the structure of the scaffold for in vivo 
expression. [2] 
Another attempt was to replace the gp16 binding domain of pRNA by 
siRNA sequence, in order to produce siRNAs in B. subtilis. This modification 
would not change the overall structure of the pRNA much. However, this 
design failed to make any product in B. subtilis. Interestingly, although the 
full-length pRNA could not be produced in E. coli, the expression worked well 
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when the sequence of pRNA was inserted into the anti-codon loop of tRNA 
scaffold. [2] Therefore, the terminal sequence may be critical for in vivo 
expression. Sequence in the 5ʹ- and 3ʹ-ends can participate in the initiation 
and termination of transcription, as well as post-transcriptional processing. 
We are planning to replace either the 5ʹ- or 3ʹ-end of pRNA by random 
sequence to investigate which parts of the RNA are required for expression. 
Unlike the sophisticated protein expression, the study of RNA expression in 
bacteria is still in its initial stage. Modifications may be needed to be made to 
the host strain, the plasmid vector, as well as the RNA scaffold itself, to 
finally develop a high-efficiency expression system. 
 
 
Figure 7 pRNA-based design constructs to be expressed in B. subtilis.  
All designs are based on wild-type pRNA (with terminator) as scaffold. (A) 
pRNA-MG, the left-hand loop replaced by MG aptamer. (B) pRNA-spi, the 
head loop replaced by spinach aptamer. (C) pRNA-MG-spi, both MG 
aptamer and spinach aptamer integrated into the left-hand loop by a 
reversed 3WJ. 
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Figure 8 MG and spinach fluorescence spectrum of pRNA-based structures 
(A) Fluorescence spectrum of living cell. The MG fluorescence was excited 
at 570 nm, and scanned from 600 to 800 nm to detect emission. The spinach 
fluorescence was excited at 450 nm, and scanned from 570 to 700 nm to 
detect emission. B. subtilis 12A without any exogenous plasmid was taken 
as negative control. (B) Fluorescence spectrum of extracted RNAs, 
measured under the same condition. 
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Figure 9 RNAs extracted from B. subtilis 12A 8% TBE PAGE with EB, MG, 
and DFHBI staining. 
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Figure 10 image of living B. subtilis cells under confocal microscope 
The fluorescence from MG aptamer was acquired in Cy5 channel. The 
fluorescence from MG aptamer was acquired in Cy2 channel. B. subtilis 12A 
without any exogenous plasmids was taken as negative control. 
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